DEF: Biohaven Ltd. Awaits FDA Decision on Troriluzole for SCA, Advances Broad Pipeline

Biohaven Ltd. is preparing for a potential commercial launch of troriluzole for spinocerebellar ataxia (SCA) in Q3 2025, while also advancing its pipeline across multiple therapeutic areas.

Summary

• Biohaven Ltd. is focused on developing innovative treatments across multiple therapeutic areas, including neurology, immunology, and oncology.
• The company's glutamate modulation platform is highlighted by troriluzole (BHV-4157), which has received Priority Review from the FDA for spinocerebellar ataxia (SCA), a rare disease affecting approximately 15,000 US patients.
• Topline data from two Phase 3 trials of troriluzole for obsessive-compulsive disorder (OCD), impacting over 3 million patients, are expected in 1H 2025 and 2H 2025, respectively.
• Biohaven is also developing extracellular protein degraders targeting IgG, IgA, and 1-AR degradation, with BHV-1400 showing a median reduction of 60% in Gd-IgA1 within four hours of administration in a Phase 1 trial for IgA nephropathy.
• First-in-human dosing with BHV-1600, a TRAP degrader of 1AR autoantibodies, has been initiated and has been well-tolerated to date without causing clinically relevant changes in innate or adaptive immunity.
• The company plans to initiate a BHV-8000 Phase 2/3 study in Parkinson's disease (PD) in 1H 2025 and will advance AD, MS and ARIA programs in late 2025.
• Pivotal major depressive disorder topline results for BHV-7000 are expected in 2H 2025, while focal epilepsy study topline results are expected in 1H 2026.
• An FDA meeting to discuss the SMA registrational path for taldefgrobep alfa (BHV-2000) is expected in 2025, and a Phase 2 study in obesity is planned for 1H 2025.
• Interim Phase 1 data with BHV-1510, a TROP2 directed ADC, is expected in 2025, and a Phase 1 trial of BHV-1530, an FGFR directed ADC, is planned for 1H 2025.
• The Annual Meeting of Shareholders will be held on May 5, 2025, to elect directors, ratify the selection of Ernst & Young LLP as the company's independent registered public accounting firm, and approve the compensation of named executive officers.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook, highlighting advancements in Biohaven's pipeline and strategic initiatives. The tone is optimistic, emphasizing the potential for transformative medicines and value creation for stakeholders.

Positives

• FDA Priority Review granted for troriluzole in SCA, indicating a potential for expedited approval.
• BHV-1400 demonstrates rapid and deep lowering of Gd-IgA1 in IgA nephropathy patients, suggesting a novel treatment approach.
• BHV-1600 is well-tolerated in first-in-human dosing, supporting further development as a TRAP degrader of 1AR autoantibodies.
• BHV-8000 shows promise as a brain-penetrant TYK2/JAK1 inhibitor with potential in neuroinflammatory and neurodegenerative disorders.
• Taldefgrobep alfa (BHV-2000) shows clinically meaningful improvements in SMA patients within a specific subgroup, and beneficial impacts on body composition parameters.

Negatives

• The overall primary endpoint of the Phase 3 study in spinal muscular atrophy (SMA) for BHV-2000 was not met.

Risks

• The FDA may not approve troriluzole for SCA, despite the Priority Review designation.
• Clinical trials for OCD and other indications may not yield positive results.
• Development of extracellular protein degraders and other novel platforms may face unforeseen challenges.
• Regulatory pathways for accelerated approval may not be available or successful.
• Clinical trials may be delayed or fail to meet endpoints.

Future Outlook

The future looks bright for our patients, our shareholders, and our global stakeholders, and we cant wait to deliver more encouraging outcomes across our portfolio in 2025 and beyond.

Management Comments

• Scientific innovation continues to flourish beyond our wildest expectations and our broad pipeline, across multiple therapeutic areas, has the potential to advance potential paradigm-shifting medicines for patients.
• Patients and their families deserve the best treatments to allow healthy living, not just the absence of disease.
• We believe our patient-first attitude and working with the urgency of Days Matter keeps our priorities aligned with the best interests of investors.
• It is a privilege to work to advance science and pursue the development of transformative medicines to treat disease.
• I cant think of many examples of healthcare companies with our lean, focused size, pursuing such an innovative, yet rigorous, data-driven approach, who possess a broad portfolio addressing such a profound and diverse array of indications.

Industry Context

Biohaven is positioning itself as a leader in precision immunology and innovative approaches to neurological and neuropsychiatric disorders, oncology, competing with larger pharmaceutical companies and other biotech firms in these spaces.

Comparison to Industry Standards

• Biohaven's approach to ADC optimization, focusing on the antibody, linker, and payload, aligns with industry trends in oncology drug development.
• The company's use of extracellular protein degraders represents a novel approach in immunology, potentially offering advantages over traditional immunosuppressive therapies.
• Biohaven's pipeline breadth, spanning neurology, immunology, and oncology, is comparable to larger pharmaceutical companies with diverse portfolios.
• The company's focus on precision medicine, particularly in immunology, mirrors the industry's shift towards targeted therapies with improved efficacy and safety profiles.
• Biohaven's collaboration with GeneQuantum and Merus is similar to other biotech companies that partner to access specialized technologies and expertise.

Related Party Transactions

• Katrina VanTyne, the sibling of Ms. Gentile, an executive of the Company, became an employee of the Company on October 3, 2022.
• In January 2024, the Company acquired Pyramid Biosciences, Inc. Dr. Coric and Mr. Childs received common shares of the Company in exchange for shares of Pyramid common stock they held immediately prior to the Pyramid acquisition.

Stakeholder Impact

• Shareholders: Potential for increased value through successful drug development and commercialization.
• Patients: Access to innovative treatments for neurological, immunological, and oncological disorders.
• Employees: Opportunities for professional growth and development within a growing biopharmaceutical company.
• Global Stakeholders: Improved healthcare outcomes and quality of life through Biohaven's advancements in medicine.

Next Steps

• Prepare for commercial launch of troriluzole in SCA, pending FDA approval in 3Q 2025.
• Await topline data from two Phase 3 OCD trials in 1H 2025 and 2H 2025, respectively.
• Complete Phase 1 testing with an optimized subcutaneous formulation of BHV-1300 in 1H 2025.
• Initiate a BHV-1310 first-in-human study in 2025.
• Initiate a Phase 2 study in Graves' Disease mid-2025.
• Complete Phase 1 trials with BHV-1400 and BHV-1600 in 1H 2025.
• Advance four molecules toward development candidates in 2025, including an IgG4 degrader, a PLA2R autoantibody degrader, an insulin autoantibody degrader, and a TSH receptor autoantibody degrader.
• Initiate a BHV-8000 Phase 2/3 study in PD in 1H 2025 and advance AD, MS and ARIA programs in late 2025.
• Await pivotal major depressive disorder topline results for BHV-7000 in 2H 2025, and focal epilepsy study topline results in 1H 2026.
• Obtain data from the laser-evoked potential study and proof-of-concept migraine study for BHV-2100 in 1H 2025.
• Attend an FDA meeting to discuss the SMA registrational path for taldefgrobep alfa (BHV-2000) in 2025, and initiate a Phase 2 study in obesity in 1H 2025.
• Report interim Phase 1 data with BHV-1510 and continue dose optimization in 2025.
• Initiate a Phase 1 trial of BHV-1530 in 1H 2025.
• Advance the Merus collaboration ADCs (undisclosed targets) and TopoIx ADCs in 2025.

Key Dates